Menu
Enrolling by invitation NCT06812533

Alleviant ALLAY-HFrEF Study

No phase Interventional Heart Failure

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Alleviant ALV1 System, Sham-Control.
Who it may be relevant to
Registry conditions: Heart Failure. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States, Australia, Belgium, Canada, Georgia +5
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Safety and Efficacy of the Alleviant No-Implant Interatrial Shunt in Patients With Heart Failure and Reduced Ejection Fraction

Overview

Prospective, multicenter, randomized, sham-controlled, double blind (patient and observer), study designed to evaluate the safety and efficacy of a percutaneously created interatrial shunt using the Alleviant ALV1 System in patients with HFrEF.

Interventions

  • Device Alleviant ALV1 System
    Creation of interatrial shunt
  • Other Sham-Control
    Cardiac imaging

Primary outcome measures

  • Composite Primary Endpoint [Time frame: 12-Month]

Eligibility criteria

Inclusion criteria

  • LVEF ≤ 40%
  • NYHA class II, III or ambulatory IV HF
  • Receiving optimal, maximally tolerated, stable GDMT

Exclusion criteria

  • Advanced heart failure
  • Life-expectancy < 12 months
  • Evidence of right heart dysfunction

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Crossover
Masking
Double blind
Primary purpose
Treatment

Study locations

United States · 35 centers
  • Keck Medical Center of USC — Los Angeles
  • UC Davis Medical Center — Sacramento
  • Scripps Clinical Research Services — San Diego
  • University of California San Francisco — San Francisco
  • Delray Medical Center — Delray Beach
  • Ascension Sacred Heart — Pensacola
  • Tampa General Hospital — Tampa
  • Atlanta VA Health Care System — Decatur
  • … and 27 more centers
Spain · 7 centers
  • Hospital Universitario A Coruna — A Coruña
  • Hospital de la Santa Creu i Sant Pau — Barcelona
  • Vall d'Hebron University Hospital Barcelona — Barcelona
  • Hospital Universitario 12 de Octubre — Madrid
  • Hospital Universitario Puerta de Hierro — Madrid
  • Hospital Clínico Universitario de Salamanca — Salamanca
  • Valencia Hospital Clinico — Valencia
Canada · 4 centers
  • Southlake Regional Hospital Centre — Newmarket
  • Centre hospitalier de l'Universite de Montreal (CHUM) — Montreal
  • Centre Integre Universitaire de Sainte et de Services Scoiiaux de l'Estrie - Centre Hospit — Montreal
  • IUCPQ - Université Laval (Quebec) — Québec
Belgium · 3 centers
  • OLV Hospital — Aalst
  • ZAS Middelheim — Antwerp
  • AZ Sint Jan Brugge — Bruges
Poland · 3 centers
  • University Clinical Hospital in Opole — Opole
  • Narodowy Instytut Kardiologii im. Stefana kardynała Wyszyńsk — Warsaw
  • Uniwesytecki Szpital Kliniczny — Wroclaw
Australia · 2 centers
  • Monash Health Victorian Heart Hospital — Clayton
  • Alfred Hospital — Melbourne
Greece · 2 centers
  • Hygeia Hospital — Athens
  • European Interbalken Medical Center — Thessaloniki
Israel · 2 centers
  • Tel Aviv Sourasky Medical Center — Tel Aviv
  • Shamir Medical Center — Zrifin
New Zealand · 2 centers
  • ChristChurch Hospital — Christchurch
  • Dunedin Hospital — Dunedin
Georgia · 1 center
  • Tbilisi Heart and Vascular — Tbilisi

Identifiers

NCT: NCT06812533 · CIP-0006

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗